Date: 2012-11-05
Type of information: Fundraising
Company: Life Science Entrepreneurs (Spain)
Investors: undisclosed private investors from Barcelona, Geneva and Basel, all active in medical applications of life sciences
Amount:
Funding type:
Planned used:
Others: Life Science Entrepreneurs, a company dedicated to the early-stage development of high-risk/very high return ventures, has announced the conclusion of a first investment for an antiplatelet drug candidate code-named NmC. Private investors have funded the assays to confirm the safety and efficacy of the cardiovascular drug NmC. This drug candidate has been licensed from a foreign university. In early 2013, Life Science Entrepreneurs S.L.U. will raise two million euro to conduct a complete set of regulatory pre-clinical assays from Spanish and foreign investors.
Therapeutic area:
